386 completed, 34 terminated, 22 unknown, 16 active not recruiting. 492 Phase 3, 40 Phase 2.
Follow Hyperlipidemias: new trials by email Literature Review of Hyperlipidemias trials Research Report on Hyperlipidemias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin, and Placebo on LDL-C in LLT-naïve Patients Laroprovstat, Rosuvastatin 1, Rosuvastatin 2 - Hypercholesterolemia | Phase 3 | Not yet recruiting | AstraZeneca | 204 | 2026-12-21 | 2026-11-12 |
| Lifestyle Changes, Mushroom Supplementation, and Bupropion to Reduce Adiposity and Cardiometabolic Risk Bupropion 150 mg, Lyophilized powder from edible mushrooms, Lifestyle Management - Cardiometabolic Syndrome, Obesity and Cardiovascular Risk | Phase 3 | Not yet recruiting | Uppsala University | 250 | 2026-10-30 | 2026-09-08 |
| A Clinical Study of Enlicitide (MK-0616) in Adults With Hyperlipidemia in India (MK-0616-038) Enlicitide Decanoate, Placebo - Hyperlipidemia, Hypercholesterolemia | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 150 | 2026-10-15 | 2026-11-02 |
| Study of Zodasiran in Adolescent Participants With Homozygous Familial Hypercholesterolemia Zodasiran - Homozygous Familial Hypercholesterolemia | Phase 3 | Recruiting | Arrowhead Pharmaceuticals | 10 | 2026-10-01 | 2026-10-26 |
| A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events Bempedoic acid, Ezetimibe, Rosuvastatin - Coronary Atherosclerosis, Mixed Dyslipidemia | Phase 3 | Not yet recruiting | Daiichi Sankyo | 103 | 2026-09-30 | 2026-09-29 |
| A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Rosuvastatin on LDL-C in Patients With Hypercholesterolaemia laroprovstat/rosuvastatin 1, laroprovstat/rosuvastatin 2, laroprovstat/rosuvastatin 3 - Hypercholesterolaemia | Phase 3 | Recruiting | AstraZeneca | 200 | 2026-09-10 | 2026-10-05 |
| A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia DR10624 Injection, Matching Placebo for DR10624 - Severe Hypertriglyceridemia (sHTG), Hypertriglyceridemia | Phase 3 | Not yet recruiting | Zhejiang Doer Biologics Co., Ltd. | 480 | 2026-08-17 | 2026-07-10 |
| A Phase III Study to Assess the Effect of FDC Laroprovstat/Rosuvastatin Compared With Laroprovstat, Rosuvastatin and Placebo on LDL-C in LLT-naïve Patients. Laroprovstat, Rosuvastatin 1, Rosuvastatin 2 - Hypercholesterolaemia | Phase 3 | Recruiting | AstraZeneca | 600 | 2026-08-12 | 2026-09-10 |
| A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia DR10624 Subcutaneous Injection, Icosapent Ethyl Oral Capsule, Matching Placebo Subcutaneous Injection - Severe Hypertriglyceridemia | Phase 3 | Not yet recruiting | Zhejiang Doer Biologics Co., Ltd. | 378 | 2026-08-01 | 2026-07-06 |
| Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children 6 to 17 Years, With Heterozygous FH lerodalcibep 300 mg Monthly SC - Familial Hypercholesterolemia - Heterozygous | Phase 3 | Enrolling by invitation | LIB Therapeutics LLC | 150 | 2026-07-20 | 2026-07-28 |
| Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days Obicetrapib 10 mg/Bempedoic Acid Placebo, Bempedoic Acid 180mg/Placebo Obicetrapib - Mixed Dyslipidemia, Hypercholesterolaemia | Phase 3 | Recruiting | A. Menarini International Licensing S.A. | 426 | 2026-05-06 | 2026-06-09 |
| A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors SHR-1918 Injection, SHR-1918 Injection Placebo - Hypercholesterolemia | Phase 2 / Phase 3 | Recruiting | Beijing Suncadia Pharmaceuticals Co., Ltd | 126 | 2026-04-30 | 2026-06-16 |
| IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia IBI306, placebo - Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | Phase 3 | Active not recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 198 | 2026-04-01 | 2026-08-14 |
| A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering Therapy SYH2053/placebo injection - Non-familial Hypercholesterolemia and Mixed Hyperlipidemia | Phase 3 | Not yet recruiting | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 900 | 2026-03-31 | 2026-02-19 |
| A Study of SHR-1918 In Participants With Hypertriglyceridemia SHR-1918/ SHR-1918 placebo - Hypertriglyceridemia | Phase 3 | Active not recruiting | Beijing Suncadia Pharmaceuticals Co., Ltd | 367 | 2026-03-31 | 2026-10-20 |
| QLC7401 Monotherapy in Non-familial Hypercholesterolemia or Mixed Dyslipidemia QLC7401, Placebo - Primary Hypercholesterolemia or Mixed Hyperlipidemia | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 510 | 2026-03-05 | 2026-03-02 |
| QLC7401 in the Treatment of Primary Hypercholesterolemia or Mixed Hyperlipidemia With Elevated Low Density Lipoprotein Cholesterol (LDL-C) QLC7401, Placebo - Primary Hypercholesterolemia or Mixed Hyperlipidemia | Phase 3 | Not yet recruiting | Qilu Pharmaceutical Co., Ltd. | 780 | 2026-03-01 | 2026-03-04 |
| A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed Hyperlipidemia SYH2053 injection, SYH2053 injection placebo - Non-familial Hypercholesterolemia and Mixed Hyperlipidemia | Phase 3 | Recruiting | CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. | 760 | 2026-02-28 | 2026-04-07 |
| A Trial to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hyperlipidemia SHR-1918, SHR-1918 placebo - Hyperlipidemia | Phase 3 | Recruiting | Beijing Suncadia Pharmaceuticals Co., Ltd | 900 | 2026-01-13 | 2026-09-10 |
| A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Obicetrapib 10 mg, Placebo - Lipidemia, Type 2 Diabetes (T2DM) | Phase 3 | Active not recruiting | NewAmsterdam Pharma | 300 | 2025-12-11 | 2026-09-09 |
Showing 20 of 492. Sign in to see all of them.
Hypercholesterolemia (275) · Dyslipidemias (68) · Hypertriglyceridemia (61) · Hyperlipoproteinemia Type II (54) · Hypertension (39) · Homozygous Familial Hypercholesterolemia (31) · Cardiovascular Diseases (27) · Atherosclerosis (26) · Coronary Disease (24) · Diabetes Mellitus (23) · Diabetes Mellitus, Type 2 (19) · Obesity (14) · Hyperlipoproteinemias (11) · Coronary Artery Disease (10)
Nutritional and Metabolic Diseases (491) · Lipid Metabolism Disorders (485) · Metabolic Diseases (482) · Dyslipidemias (424) · Vascular Diseases (94) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (84) · Metabolism, Inborn Errors (82) · Cardiovascular Diseases (81) · Genetic Diseases, Inborn (80) · Lipid Metabolism, Inborn Errors (80) · Hyperlipoproteinemias (79) · Glucose Metabolism Disorders (45) · Endocrine System Diseases (44) · Pathological Conditions, Signs and Symptoms (36)
Atorvastatin (93) · Ezetimibe (87) · Rosuvastatin Calcium (60) · Simvastatin (56) · evolocumab (31) · alirocumab (24) · Fenofibrate (19) · 1-((1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl)acetyl)piperidine-4-acetic acid (13) · ALN-PCS (13) · Ezetimibe, Simvastatin Drug Combination (13) · torcetrapib (13) · Pravastatin (12) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (10) · pitavastatin (10) · Niacin (9)
Organon and Co (59) · AstraZeneca (34) · Amgen (27) · Merck Sharp & Dohme LLC (24) · Sanofi (22) · Pfizer (20) · Novartis Pharmaceuticals (16) · Takeda (16) · Regeneron Pharmaceuticals (9) · Arrowhead Pharmaceuticals (8) · Pfizer's Upjohn has merged with Mylan to form Viatris Inc. (8) · Kowa Research Europe (7) · LIB Therapeutics LLC (7) · Esperion Therapeutics, Inc. (6) · Kastle Therapeutics, LLC (6)
United States (196) · Canada (122) · Netherlands (78) · Spain (73) · Germany (71) · South Africa (71) · United Kingdom (66) · France (65) · Czechia (63) · China (58) · South Korea (58) · Italy (57) · Poland (55) · Hungary (52) · Israel (50)
Russell Esterline (8) · Ron Haberman, MD (5) · Dragos Budinski, Med Dr. (4) · Evan A Stein, MD PhD (4) · Dragos Budinski, MD (3)
PMID 33078867, PMID 21518985, PMID 27777279, PMID 30183102, PMID 34298554, PMID 28304227, PMID 29685591, PMID 35277540, PMID 25614280, PMID 27578134, PMID 28964736, PMID 32609313, PMID 35916348, PMID 37994400, PMID 28391886, PMID 33990512, PMID 37565307, PMID 37658997, PMID 38063346, PMID 38757725, PMID 41604274, PMID 17407645, PMID 19029469, PMID 21401833, PMID 21613319, PMID 22087637, PMID 22500948, PMID 23325450, PMID 24014831, PMID 25269777, PMID 25431239, PMID 25893544, PMID 27206952, PMID 27418543, PMID 27596132, PMID 27939227, PMID 28304242, PMID 29716940, PMID 32187462, PMID 34989797, PMID 36520008, PMID 37282500, PMID 37786277, PMID 40064331, PMID 40587053, PMID 41211918, PMID 41903707, PMID 12034651, PMID 12719279, PMID 15311720
2015 (10), 2005 (9), 2017 (7), 2023 (7), 2025 (6), 2014 (5), 2008 (2), 2016 (2), 2004 (1), 2018 (1), 2019 (1), N01HC95178 (1), N01HC95179 (1), N01HC95180 (1), N01HC95181 (1)